You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGliquidone
Accession NumberDB01251
TypeSmall Molecule
GroupsApproved
DescriptionGliquidone is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Structure
Thumb
Synonyms
Glurenorm
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DevotanMenarini
FordiabHexpharm Jaya
GlidiabSoho
GlunormalYing Yuan
GlurenorGuidotti
GlurenormBoehringer Ingelheim
Jie ShiTianjin Institute of Pharmaceutical Research Pharmaceutical
Ka Rui LinAnjielun
LodemDexa Medica
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIC7C2QDD75P
CAS number33342-05-1
WeightAverage: 527.632
Monoisotopic: 527.209006493
Chemical FormulaC27H33N3O6S
InChI KeyInChIKey=LLJFMFZYVVLQKT-UHFFFAOYSA-N
InChI
InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)
IUPAC Name
1-cyclohexyl-3-{4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzenesulfonyl}urea
SMILES
COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,3-isoquinolinediones. These are isoquinoline derivatives carrying one C=O group at positions 1, and 3 respectively.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoquinolines and derivatives
Sub Class1,3-isoquinolinediones
Direct Parent1,3-isoquinolinediones
Alternative Parents
Substituents
  • 1,3-isoquinolinedione
  • Isoquinolone
  • Tetrahydroisoquinoline
  • Benzenesulfonamide
  • Phenethylamine
  • Anisole
  • Sulfonylurea
  • Dicarboximide
  • Cyclohexylamine
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the treatment of diabetes mellitus type 2.
PharmacodynamicsGliquidone is an anti-diabetic drug in the sulfonylurea class. In patients with diabetes mellitus, there is a deficiency or absence of a hormone manufactured by the pancreas called insulin. Insulin is the main hormone responsible for the control of sugar in the blood. Gliquidone is an antidiabetic medication which is used in those patients with adult maturity onset or non-insulin dependent diabetes (NIDDM). It works by lowering blood sugar levels by stimulating the production and release of insulin from the pancreas. It also promotes the movement of sugar from the blood into the cells in the body which need it.
Mechanism of actionThe mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeThe mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier+0.625
Caco-2 permeable-0.6185
P-glycoprotein substrateSubstrate0.7457
P-glycoprotein inhibitor IInhibitor0.6115
P-glycoprotein inhibitor IIInhibitor0.805
Renal organic cation transporterNon-inhibitor0.7921
CYP450 2C9 substrateSubstrate0.5166
CYP450 2D6 substrateNon-substrate0.8162
CYP450 3A4 substrateSubstrate0.594
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.6454
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5173
Ames testNon AMES toxic0.6124
CarcinogenicityNon-carcinogens0.7477
BiodegradationNot ready biodegradable0.8693
Rat acute toxicity2.3506 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8418
hERG inhibition (predictor II)Inhibitor0.6182
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180-182U.S. Patent 3,708,486.
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0022 mg/mLALOGPS
logP3.59ALOGPS
logP4.14ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area121.88 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity139.48 m3·mol-1ChemAxon
Polarizability57.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 3,708,486.

General ReferencesNot Available
External Links
ATC CodesA10BB08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololAcebutolol may increase the hypoglycemic activities of Gliquidone.
AcenocoumarolGliquidone may increase the anticoagulant activities of Acenocoumarol.
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Gliquidone.
AlogliptinAlogliptin may increase the hypoglycemic activities of Gliquidone.
AlprenololAlprenolol may increase the hypoglycemic activities of Gliquidone.
AripiprazoleThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Aripiprazole.
ArotinololArotinolol may increase the hypoglycemic activities of Gliquidone.
Arsenic trioxideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Arsenic trioxide.
ArticaineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Atazanavir.
AtenololAtenolol may increase the hypoglycemic activities of Gliquidone.
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Gliquidone.
BefunololBefunolol may increase the hypoglycemic activities of Gliquidone.
BendroflumethiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bendroflumethiazide.
BetamethasoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Betamethasone.
BetaxololBetaxolol may increase the hypoglycemic activities of Gliquidone.
BevantololBevantolol may increase the hypoglycemic activities of Gliquidone.
BezafibrateBezafibrate may increase the hypoglycemic activities of Gliquidone.
BisoprololBisoprolol may increase the hypoglycemic activities of Gliquidone.
BopindololBopindolol may increase the hypoglycemic activities of Gliquidone.
BrexpiprazoleThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Brexpiprazole.
BufuralolBufuralol may increase the hypoglycemic activities of Gliquidone.
BumetanideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bumetanide.
BupranololBupranolol may increase the hypoglycemic activities of Gliquidone.
BuserelinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Buserelin.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Gliquidone.
CarbocisteineThe risk or severity of adverse effects can be increased when Gliquidone is combined with Carbocisteine.
CarteololCarteolol may increase the hypoglycemic activities of Gliquidone.
CarvedilolCarvedilol may increase the hypoglycemic activities of Gliquidone.
CeliprololCeliprolol may increase the hypoglycemic activities of Gliquidone.
CeritinibThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ceritinib.
ChloramphenicolThe metabolism of Gliquidone can be decreased when combined with Chloramphenicol.
ChlorothiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorothiazide.
ChlorpropamideGliquidone may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorthalidone.
CimetidineThe serum concentration of Gliquidone can be increased when it is combined with Cimetidine.
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Gliquidone.
ClofibrateClofibrate may increase the hypoglycemic activities of Gliquidone.
ClozapineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Clozapine.
CorticotropinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Cortisone acetate.
Cyproterone acetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dabrafenib.
DanazolThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Danazol.
DarunavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Darunavir.
DesogestrelThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dexamethasone.
DiazoxideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Diazoxide.
DicoumarolGliquidone may increase the anticoagulant activities of Dicoumarol.
DienogestThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dienogest.
DisopyramideGliquidone may increase the hypoglycemic activities of Disopyramide.
DrospirenoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Drospirenone.
DulaglutideDulaglutide may increase the hypoglycemic activities of Gliquidone.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Gliquidone.
EpinephrineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Epinephrine.
EsmololEsmolol may increase the hypoglycemic activities of Gliquidone.
EstradiolThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Estradiol.
Estrone sulfateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Estrone sulfate.
Etacrynic acidThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Etacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Gliquidone is combined with Ethanol.
Ethinyl EstradiolThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethinyl Estradiol.
Ethyl biscoumacetateGliquidone may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethynodiol diacetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethynodiol diacetate.
EtofibrateEtofibrate may increase the hypoglycemic activities of Gliquidone.
EtonogestrelThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Etonogestrel.
EverolimusThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Everolimus.
ExenatideExenatide may increase the hypoglycemic activities of Gliquidone.
FenofibrateFenofibrate may increase the hypoglycemic activities of Gliquidone.
FluconazoleThe serum concentration of Gliquidone can be increased when it is combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Fludrocortisone.
FosamprenavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Fosamprenavir.
FurosemideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Furosemide.
GemfibrozilGemfibrozil may increase the hypoglycemic activities of Gliquidone.
GliclazideGliquidone may increase the hypoglycemic activities of Gliclazide.
GlimepirideGliquidone may increase the hypoglycemic activities of Glimepiride.
GlipizideGliquidone may increase the hypoglycemic activities of Glipizide.
GlyburideGliquidone may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin.
HistrelinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Histrelin.
HydrochlorothiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydroxyprogesterone caproate.
IloperidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Iloperidone.
IndapamideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Indapamide.
IndenololIndenolol may increase the hypoglycemic activities of Gliquidone.
IndinavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Indinavir.
Insulin AspartGliquidone may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirGliquidone may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineGliquidone may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineGliquidone may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanGliquidone may increase the hypoglycemic activities of Insulin Human.
Insulin LisproGliquidone may increase the hypoglycemic activities of Insulin Lispro.
LabetalolLabetalol may increase the hypoglycemic activities of Gliquidone.
LanreotideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lanreotide.
LanreotideGliquidone may increase the hypoglycemic activities of Lanreotide.
LeuprolideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide.
LevobunololLevobunolol may increase the hypoglycemic activities of Gliquidone.
LevonorgestrelThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Levonorgestrel.
LinagliptinLinagliptin may increase the hypoglycemic activities of Gliquidone.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Gliquidone.
LiraglutideLiraglutide may increase the hypoglycemic activities of Gliquidone.
LopinavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lopinavir.
LurasidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lurasidone.
MecaserminGliquidone may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Medroxyprogesterone acetate.
Megestrol acetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Megestrol acetate.
MestranolThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Mestranol.
MethotrimeprazineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methyclothiazide.
MethylprednisoloneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methylprednisolone.
MetipranololMetipranolol may increase the hypoglycemic activities of Gliquidone.
MetolazoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Metolazone.
MetoprololMetoprolol may increase the hypoglycemic activities of Gliquidone.
MetreleptinMetreleptin may increase the hypoglycemic activities of Gliquidone.
MiconazoleMiconazole may increase the hypoglycemic activities of Gliquidone.
MifepristoneGliquidone may increase the hypoglycemic activities of Mifepristone.
NadololNadolol may increase the hypoglycemic activities of Gliquidone.
NateglinideGliquidone may increase the hypoglycemic activities of Nateglinide.
NelfinavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Nelfinavir.
NiacinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Niacin.
NilotinibThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Nilotinib.
NorethisteroneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Norgestimate.
OctreotideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Octreotide.
OctreotideGliquidone may increase the hypoglycemic activities of Octreotide.
OlanzapineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Olanzapine.
OxprenololOxprenolol may increase the hypoglycemic activities of Gliquidone.
PaliperidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Paliperidone.
PasireotideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pasireotide.
PasireotideGliquidone may increase the hypoglycemic activities of Pasireotide.
PenbutololPenbutolol may increase the hypoglycemic activities of Gliquidone.
PentamidineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pentamidine.
PentamidineGliquidone may increase the hypoglycemic activities of Pentamidine.
PhenindioneGliquidone may increase the anticoagulant activities of Phenindione.
PhenprocoumonGliquidone may increase the anticoagulant activities of Phenprocoumon.
PindololPindolol may increase the hypoglycemic activities of Gliquidone.
PioglitazonePioglitazone may increase the hypoglycemic activities of Gliquidone.
PiperazineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pipotiazine.
PolythiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Polythiazide.
PractololPractolol may increase the hypoglycemic activities of Gliquidone.
PrednisoloneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisone.
ProbenecidThe protein binding of Gliquidone can be decreased when combined with Probenecid.
ProgesteroneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Progesterone.
PropranololPropranolol may increase the hypoglycemic activities of Gliquidone.
QuetiapineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quetiapine.
QuinethazoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quinethazone.
QuinineGliquidone may increase the hypoglycemic activities of Quinine.
RanitidineThe serum concentration of Gliquidone can be increased when it is combined with Ranitidine.
RepaglinideGliquidone may increase the hypoglycemic activities of Repaglinide.
RifampicinThe serum concentration of Gliquidone can be decreased when it is combined with Rifampicin.
RisperidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ritonavir.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Gliquidone.
SaquinavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Saquinavir.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Gliquidone.
SirolimusThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Sirolimus.
SitagliptinSitagliptin may increase the hypoglycemic activities of Gliquidone.
SotalolSotalol may increase the hypoglycemic activities of Gliquidone.
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Gliquidone.
SulfamethoxazoleSulfamethoxazole may increase the hypoglycemic activities of Gliquidone.
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Gliquidone.
SunitinibGliquidone may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Tacrolimus.
TemsirolimusThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Temsirolimus.
TimololTimolol may increase the hypoglycemic activities of Gliquidone.
TipranavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Tipranavir.
TolazamideGliquidone may increase the hypoglycemic activities of Tolazamide.
TolbutamideGliquidone may increase the hypoglycemic activities of Tolbutamide.
TorasemideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Torasemide.
TriamcinoloneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Triamcinolone.
TrichlormethiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Trichlormethiazide.
TriptorelinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Triptorelin.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Gliquidone.
VildagliptinVildagliptin may increase the hypoglycemic activities of Gliquidone.
VoriconazoleThe serum concentration of Gliquidone can be increased when it is combined with Voriconazole.
VorinostatThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Vorinostat.
WarfarinGliquidone may increase the anticoagulant activities of Warfarin.
ZiprasidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sulfonylurea receptor activity
Specific Function:
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name:
ABCC8
Uniprot ID:
Q09428
Molecular Weight:
176990.36 Da
References
  1. Gribble FM, Ashcroft FM: Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism. 2000 Oct;49(10 Suppl 2):3-6. [PubMed:11078468 ]
  2. Harrower A: Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism. 2000 Oct;49(10 Suppl 2):7-11. [PubMed:11078469 ]
  3. Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, Ashcroft FM: Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001 Aug;44(8):1019-25. [PubMed:11484080 ]
  4. Reimann F, Ashcroft FM, Gribble FM: Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. [PubMed:11574406 ]
  5. Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. [PubMed:12475777 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Inward rectifier potassium channel activity
Specific Function:
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward...
Gene Name:
KCNJ8
Uniprot ID:
Q15842
Molecular Weight:
47967.455 Da
References
  1. Szewczyk A, Wojcik G, Lobanov NA, Nalecz MJ: The mitochondrial sulfonylurea receptor: identification and characterization. Biochem Biophys Res Commun. 1997 Jan 23;230(3):611-5. [PubMed:9015372 ]
  2. Sato T, Costa AD, Saito T, Ogura T, Ishida H, Garlid KD, Nakaya H: Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8. Epub 2005 Sep 20. [PubMed:16174795 ]
  3. Hill RA, Rudra S, Peng B, Roane DS, Bounds JK, Zhang Y, Adloo A, Lu T: Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113. [PubMed:12670661 ]
Comments
comments powered by Disqus
Drug created on March 30, 2007 08:35 / Updated on August 17, 2016 12:23